Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01253707 · ClinicalTrials.gov registry record · Phase 1
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 111
- Enrollment target
NCT01253707: Completed Phase 1 study, sponsored by Amgen.
NCT01253707 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 111 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01253707, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 111 participants
- Enrollment target
Study Summary
First in human, open-label, sequential dose escalation and expansion study of AMG 337 in subjects with advanced solid tumors.
Interventions
- DRUG AMG 337
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2010-12-08 |
| Est. Completion | 2016-12-13 |
| Phase | Phase 1 |
What the finished NCT01253707 record still lists
NCT01253707 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% higher).
The record links to 0 conditions, and to 1 intervention - of which AMG 337 is the first listed.
NCT01253707 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01253707 about?
NCT01253707 is a clinical study titled "A Study of AMG 337 in Subjects With Advanced Solid Tumors". First in human, open-label, sequential dose escalation and expansion study of AMG 337 in subjects with advanced solid tumors.
What is the current status of trial NCT01253707?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 111 participants. The study started on 2010-12-08. Estimated completion is 2016-12-13.
What interventions are being tested in trial NCT01253707?
The interventions under investigation include: AMG 337 (DRUG).
Who is sponsoring clinical trial NCT01253707?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01253707's enrollment target sits among peer trials
111 512th of 2000 higher than 1,487 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI